Auxiliary treatment of the calcium channel alpha2-garma subunit inhibitors for postherpetic neuralgia: a randomized, double-blind controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002171

Enrollment

Unknown

Registered

2012-05-13

Start date

2010-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

group A:placebo

group B:pregabalin 225mg/d

group C:pregabalin 375mg/d

group D:gabapentin 900mg/d

Eligibility

Sex/Gender

All

Age

40 Years to 82 Years

Inclusion criteria

Inclusion criteria: All patients were screened following inclusion criteria: Average pain intensity score (VAS) > 5; Neuralgia more than 3 months; Age > 30Y; Lung, liver, kidney and other vital organs had no diseases; Without a blood abnormal coagulation time; Without nausea, vomiting, dizziness, constipation, urinary retention, etc; No opioid allergy and abusers; Accept drug treatment for neuropathic pain; Agree to participate in this study and informed agreement signed.

Exclusion criteria

Exclusion criteria: Beyond the scope of herpes, spirit and/or cognitive impairment, diabetes, hypertension disease, recent severe myocardial infarction, kidney and liver abnormal function, electrolyte abnormalities, allergic constitution, severe obesity, pregnant women and nursing patients.

Design outcomes

Primary

Measure	Time frame
VAS;EMSIS;SPI;PGI;	—

Contacts

Public ContactDaying Zhang

zhangdy666@gmail.com+86 13507913595

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026